Skip to main content

Table 7 Additional clinical trials in MPM utilizing checkpoint inhibitors

From: Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma

Trial acronym or title Trial identifier Treatment Phase Primary objective (s) Completion date Report status References
Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, and Esophageal Carcinomas, or Pleural Mesotheliomas NCT03233724 Experimental: 1
(Dose Escalation)
Decitabine (DAC) –Tetrahydrouridine (THU) + pembrolizumab at escalating doses
Experimental: 2
Dose Expansion
DAC-THU + pembrolizumab at the dose established in Arm 1
I/II Maximum Tolerated Dose (MTD)
ORR – to determine if the combination is associated with an ORR which exceeds that of Pembrolizumab alone in patients who have PD-L1 expression of at least 50% and those who do not
Estimated Study Completion Date: December 31, 2026 Running no interim results as yet  
ORIGIN
Overcoming Resistance to Immunotherapy Combining Gemcitabine With Atezolizumab in Advanced NSCLC and Mesothelioma Progressing Under Immune-checkpoint Inhibitors or Gemcitabine. A Multicenter, Single-arm, Open Label Phase II Trial With Two Cohorts
NCT04480372 Cohort 1. NSCLC
Cohort 2. Inoperable MPM
gemcitabine 1000 mg/m2 on day 1 and day 8 of each cycle (every 3 weeks) and with atezolizumab 1200 mg on day 1 of each cycle (every 3 weeks)
II ORR Estimated Primary Completion Date:
April 2025
Estimated Study Completion Date: December 2025
Not yet recruiting